Vor Bio Announces Board Appointments Of Andrew Levin, M.D., Ph.D., And Forbion’s Wouter Joustra

Vor Biopharma Inc., a clinical-stage biotechnology company focused on transforming treatments for autoimmune diseases, announced the appointment of two new members to its Board of Directors: Andrew Levin, M.D., Ph.D., Partner at RA Capital Management, and Wouter Joustra, General Partner at Forbion. Their appointments come shortly after the company’s recently announced $150 million PIPE financing, in which both firms participated.

Jean-Paul Kress, M.D., Chief Executive Officer and Chairman of Vor Bio, stated that both new board members bring strong and complementary expertise in life sciences investment, funding strategy, and corporate governance. He noted that their insights will be especially valuable as the company advances its global Phase 3 programs and works toward building long-term value for shareholders.

Dr. Levin is a Partner on the investment team at RA Capital Management, where he has played a key role in supporting biopharmaceutical companies across various stages of development. His academic background includes a B.S. in mechanical engineering from Princeton University, an M.D. from Harvard Medical School, and a Ph.D. in biomedical engineering from the Massachusetts Institute of Technology. He will fill the board seat previously held by Sarah Reed, General Counsel at RA Capital, who recently resigned.

Dr. Levin expressed enthusiasm about joining the board, noting that Vor Bio is entering an important stage as it moves telitacicept through global Phase 3 development. He highlighted the company’s focus on disciplined capital use and long-term growth as key reasons he is eager to contribute.

Wouter Joustra, the second new appointee, is a General Partner at Forbion. He leads various responsibilities across fund management, late-stage private investments, crossover strategies, and public market opportunities. He has served on the boards of several high-growth biotech companies through acquisitions and currently serves on multiple public and private life science boards. He earned an M.Sc. in Business Administration and a B.Sc. in International Business and Management from the University of Groningen.

Mr. Joustra commented that Vor Bio has built a strong foundation with telitacicept and said he looks forward to supporting the company’s growth as it continues to expand its late-stage clinical programs. With these appointments, Vor Bio strengthens its Board of Directors at a time when the company is progressing through key clinical milestones and preparing for future growth.